文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

一个 EMT 驱动的可变剪接程序发生在人类乳腺癌中,并调节细胞表型。

An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.

机构信息

Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

出版信息

PLoS Genet. 2011 Aug;7(8):e1002218. doi: 10.1371/journal.pgen.1002218. Epub 2011 Aug 18.


DOI:10.1371/journal.pgen.1002218
PMID:21876675
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3158048/
Abstract

Epithelial-mesenchymal transition (EMT), a mechanism important for embryonic development, plays a critical role during malignant transformation. While much is known about transcriptional regulation of EMT, alternative splicing of several genes has also been correlated with EMT progression, but the extent of splicing changes and their contributions to the morphological conversion accompanying EMT have not been investigated comprehensively. Using an established cell culture model and RNA-Seq analyses, we determined an alternative splicing signature for EMT. Genes encoding key drivers of EMT-dependent changes in cell phenotype, such as actin cytoskeleton remodeling, regulation of cell-cell junction formation, and regulation of cell migration, were enriched among EMT-associated alternatively splicing events. Our analysis suggested that most EMT-associated alternative splicing events are regulated by one or more members of the RBFOX, MBNL, CELF, hnRNP, or ESRP classes of splicing factors. The EMT alternative splicing signature was confirmed in human breast cancer cell lines, which could be classified into basal and luminal subtypes based exclusively on their EMT-associated splicing pattern. Expression of EMT-associated alternative mRNA transcripts was also observed in primary breast cancer samples, indicating that EMT-dependent splicing changes occur commonly in human tumors. The functional significance of EMT-associated alternative splicing was tested by expression of the epithelial-specific splicing factor ESRP1 or by depletion of RBFOX2 in mesenchymal cells, both of which elicited significant changes in cell morphology and motility towards an epithelial phenotype, suggesting that splicing regulation alone can drive critical aspects of EMT-associated phenotypic changes. The molecular description obtained here may aid in the development of new diagnostic and prognostic markers for analysis of breast cancer progression.

摘要

上皮-间质转化(EMT)是胚胎发育过程中重要的机制,在恶性转化过程中起着关键作用。虽然已经了解了 EMT 的转录调控,但几个基因的选择性剪接也与 EMT 进展相关,但剪接变化的程度及其对伴随 EMT 的形态转化的贡献尚未得到全面研究。我们使用已建立的细胞培养模型和 RNA-Seq 分析,确定了 EMT 的选择性剪接特征。编码 EMT 依赖性细胞表型变化的关键驱动基因,如肌动蛋白细胞骨架重塑、细胞-细胞连接形成的调节以及细胞迁移的调节,在 EMT 相关的选择性剪接事件中富集。我们的分析表明,大多数 EMT 相关的选择性剪接事件是由 RBFOX、MBNL、CELF、hnRNP 或 ESRP 类剪接因子的一个或多个成员调节的。EMT 选择性剪接特征在人乳腺癌细胞系中得到了验证,这些细胞系可以仅根据其 EMT 相关的剪接模式分为基底和腔型。在原发性乳腺癌样本中也观察到 EMT 相关的选择性 mRNA 转录本的表达,表明 EMT 依赖性剪接变化在人类肿瘤中普遍发生。通过表达上皮特异性剪接因子 ESRP1 或在间质细胞中耗尽 RBFOX2 来测试 EMT 相关的选择性剪接的功能意义,这两种方法都引起了细胞形态和向上皮表型的运动的显著变化,表明剪接调节本身可以驱动 EMT 相关表型变化的关键方面。这里获得的分子描述可能有助于开发新的诊断和预后标志物,用于分析乳腺癌的进展。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/0fb46598d6a9/pgen.1002218.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/2720fd95bd8b/pgen.1002218.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/4135d05ce35d/pgen.1002218.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/47a584f7bc7a/pgen.1002218.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/f140dd43f1d4/pgen.1002218.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/8211d30f1a6d/pgen.1002218.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/7722c2e18360/pgen.1002218.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/0fb46598d6a9/pgen.1002218.g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/2720fd95bd8b/pgen.1002218.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/4135d05ce35d/pgen.1002218.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/47a584f7bc7a/pgen.1002218.g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/f140dd43f1d4/pgen.1002218.g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/8211d30f1a6d/pgen.1002218.g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/7722c2e18360/pgen.1002218.g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fcbd/3158048/0fb46598d6a9/pgen.1002218.g007.jpg

相似文献

[1]
An EMT-driven alternative splicing program occurs in human breast cancer and modulates cellular phenotype.

PLoS Genet. 2011-8-18

[2]
Splicing factor ratio as an index of epithelial-mesenchymal transition and tumor aggressiveness in breast cancer.

Oncotarget. 2017-1-10

[3]
The RNA-binding protein Rbfox2: an essential regulator of EMT-driven alternative splicing and a mediator of cellular invasion.

Oncogene. 2013-2-25

[4]
A Regulatory Axis between Epithelial Splicing Regulatory Proteins and Estrogen Receptor α Modulates the Alternative Transcriptome of Luminal Breast Cancer.

Int J Mol Sci. 2022-7-16

[5]
Coregulation of alternative splicing by hnRNPM and ESRP1 during EMT.

RNA. 2018-7-24

[6]
Splicing factor controls ER-positive breast cancer by altering metabolic pathways.

EMBO Rep. 2019-1-21

[7]
Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.

Mol Biol Rep. 2021-1

[8]
The oncogenic kinase NEK2 regulates an RBFOX2-dependent pro-mesenchymal splicing program in triple-negative breast cancer cells.

J Exp Clin Cancer Res. 2021-12-20

[9]
A combinatorially regulated RNA splicing signature predicts breast cancer EMT states and patient survival.

RNA. 2020-5-28

[10]
Roles and Regulation of Epithelial Splicing Regulatory Proteins 1 and 2 in Epithelial-Mesenchymal Transition.

Int Rev Cell Mol Biol. 2016

引用本文的文献

[1]
Best evidence linking the extracellular factor TGF-β to cancer-associated alternative splicing programs.

BBA Adv. 2024-12-18

[2]
ESRP1 exerts anti-tumor role by promoting ferroptosis in diffuse-type gastric cancer.

J Exp Clin Cancer Res. 2025-6-18

[3]
Aberrant Splicing as a Mechanism for Resistance to Cancer Therapies.

Cancers (Basel). 2025-4-21

[4]
The role of ESRP1 in solid tumor development through the regulation of CD44 splicing and EMT processes.

Front Oncol. 2025-2-12

[5]
The Rbfox1/LASR complex controls alternative pre-mRNA splicing by recognition of multipart RNA regulatory modules.

Genes Dev. 2025-3-3

[6]
Global profiling of alternative splicing in non-small cell lung cancer reveals novel histological and population differences.

Oncogene. 2025-4

[7]
Down-regulation of ESRP2 inhibits breast cancer cell proliferation via inhibiting cyclinD1.

Sci Rep. 2024-11-18

[8]
RBFOX2 as a regulatory linchpin in cancer: insights from a comprehensive review of its roles in tumorigenesis.

Am J Cancer Res. 2024-10-25

[9]
Isoform-Level Transcriptome Analysis of Peripheral Blood Mononuclear Cells from Breast Cancer Patients Identifies a Disease-Associated Isoform.

Cancers (Basel). 2024-9-16

[10]
The transcription factor ZNF248 promotes colorectal cancer metastasis by binding to ZEB1.

J Cancer. 2024-8-19

本文引用的文献

[1]
CD44 splice isoform switching in human and mouse epithelium is essential for epithelial-mesenchymal transition and breast cancer progression.

J Clin Invest. 2011-3

[2]
A systems view of epithelial-mesenchymal transition signaling states.

Clin Exp Metastasis. 2010-12-31

[3]
Sam68 regulates EMT through alternative splicing-activated nonsense-mediated mRNA decay of the SF2/ASF proto-oncogene.

J Cell Biol. 2010-9-27

[4]
Core epithelial-to-mesenchymal transition interactome gene-expression signature is associated with claudin-low and metaplastic breast cancer subtypes.

Proc Natl Acad Sci U S A. 2010-8-16

[5]
An ESRP-regulated splicing programme is abrogated during the epithelial-mesenchymal transition.

EMBO J. 2010-8-13

[6]
Exon-level microarray analyses identify alternative splicing programs in breast cancer.

Mol Cancer Res. 2010-7-6

[7]
Genome-wide analysis of PTB-RNA interactions reveals a strategy used by the general splicing repressor to modulate exon inclusion or skipping.

Mol Cell. 2009-12-25

[8]
Conserved developmental alternative splicing of muscleblind-like (MBNL) transcripts regulates MBNL localization and activity.

RNA Biol. 2010-1-21

[9]
The epithelial splicing factors ESRP1 and ESRP2 positively and negatively regulate diverse types of alternative splicing events.

RNA Biol. 2009-11-22

[10]
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features.

Proc Natl Acad Sci U S A. 2009-8-18

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索